Xcout Intel
BlossomHill Therapeutics, Inc.
Blossomhill Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded in June 2020 and is headquartered in San Diego, CA.
Subscribe to see BlossomHill Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
BlossomHill Therapeutics, Inc. at a glance
BlossomHill Therapeutics, Inc. is a biotech company headquartered in San Diego, United States. It is publicly listed (BLSM) with a market capitalisation of $431.3M. Xcout tracks 35 named people at BlossomHill Therapeutics, Inc., including Jingrong Jean Cui (President and Chief Executive Officer).
BlossomHill Therapeutics, Inc. leadership
- Jingrong Jean CuiPresident and Chief Executive Officer
- Jason A KeyesCFO & Executive VP
- Jason KeyesExecutive Vice President and Chief Financial Officer
- Geoff OxnardChief Medical Officer & Executive VP
- Geoff Oxnard, M.D.Executive Vice President and Chief Medical Officer
- Vincent Liptak, J.D., Ph.D., MBAExecutive Vice President and General Counsel
29 more named people on record for BlossomHill Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Recent BlossomHill Therapeutics, Inc. news
- IPOBlossomHill Therapeutics, Inc. Common Stock IPO on NASDAQ
- IPOIPO registration (S-1)
- IPOIPO registration (S-1)
- IPOIPO registration (S-1)
5 corporate events on record, with sources — see the full timeline →
BlossomHill Therapeutics, Inc. competitors
A few of BlossomHill Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Alterome Therapeutics, Inc. is a clinical-stage precision oncology company headquartered in San Diego, California, founded in 2021. The privately held biotech firm focuses on developing targeted therapies to address genomically defined cancer drivers and intractable oncological targets.
Breakthru Medicine is a privately held biotechnology company headquartered in Phoenix, Arizona. Founded in 2024 by oncology experts, the company advances a portfolio of innovative cancer therapeutics designed to address critical unmet clinical needs.
858 Therapeutics is a preclinical biotechnology company focused on the discovery and development of novel small molecule therapeutics for cancer treatment. The company concentrates on targeting RNA-modifying enzymes and related pathways to develop oncology drugs that address unmet medical needs. It serves patients with cancer by advancing innovative targeted therapies through the drug discovery pipeline.
Oncternal Therapeutics, Inc. is a clinical-stage oncology company founded in 2013 and headquartered in San Diego, California, focused on developing new cancer treatments.
RayThera is a small molecule drug discovery company founded in August 2023, headquartered in San Diego, CA, United States. Its mission is to develop safer, more effective therapeutics by advancing drug discovery with proven expertise and adaptable approaches. The company focuses on transformative therapies for unmet medical needs.
Get BlossomHill Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about BlossomHill Therapeutics, Inc.? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on BlossomHill Therapeutics, Inc. in Xcout Intel
- 35 named people with titles, LinkedIn and board committees
- 5 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access